Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along
Executive Summary
The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data
You may also be interested in...
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial
Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer
Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial
Wyeth To Re-Submit Viviant This Year, Expects FDA Advisory Review
Merged Pfizer/Wyeth will likely have to choose between Viviant and Fablyn.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: